Breath of Life: Duke Inventors Secure $5M for Novel Oxygenation Startup
Duke clinician partners with Duke engineers to tackle an elusive critical care challenge: Can oxygen be delivered directly into the bloodstream through a catheter?
Colleagues off the Court: Duke and UNC Champion Research and Innovation on Capitol Hill
From Google’s search to 3D printing, from MRIs to mRNA vaccines, countless products and services that make our lives better started as university born innovations from research.
Duke University ranks 24th worldwide for patents granted to academic institutions
Duke researchers are pioneering inventors and Duke is successfully commercializing these inventions for the benefit of the public.
Donald Patrick McDonnell, PhD, Wins 2025 Baxter Prize for Entrepreneurship
Professor Donald McDonnell (PCB, SOM) is a serial inventor with multiple commercialized technologies, including FDA-approved breast cancer drug ORSERDU.
Finding the right fit: inventive Duke students get crash course in commercializing their technologies
Making customer calls and polishing pitches – Duke’s innovation ecosystem collaborates to offer Duke graduate and professional students a hands-on technology commercialization bootcamp.
Interdisciplinarity and impact shine at Duke Research and Innovation Summit 2025
The annual gathering of the Duke research community emphasized how innovators are making an impact through their research.
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
Tune Therapeutics is a Duke University start-up and Duke Capital Partners portfolio company developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).
Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform
Tavros Therapeutics was co-founded by Eoin McDonnell, graduate of the Duke University Molecular Cancer Biology PhD Program, and Associate Professor Kris Wood (Pharmacology and Cancer Biology, SOM).
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
Humacyte is a Duke University start-up out of the lab of Dr. Laura Niklason (formerly Anesthesiology, SOM), co-founded with Drs. Juliana Blum and Shannon Dahl.